Beginner's Mind

The current pandemic SARS Cov 2 is shining a light on vaccine development. Since December 2019, the novel coronavirus is known amongst scientists. The virus is highly contagious. As a first measure, many governments all over the world have ordered a complete lockdown of the countries.

Some politicians make reverting life back to normal dependent on the existence of medication and/or vaccine. How long does it take to develop a vaccine against this novel coronavirus?

In this episode, the vaccine development expert Ericht Tauber, CEO, and founder of Themis Bioscience, explains what it takes to develop a novel vaccine and also gives an outlook on the timeline.

It was a huge pleasure to be accompanied by Elisabeth Pfneisl, Addendum.org, during the recording of this interview.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)
Erich Tauber (https://www.linkedin.com/in/erich-tauber-0ba8a111/)

Companies:
Addendum.org (https://www.addendum.org/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Themis BioScience (https://themisbio.com/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly in the Q&A. The questions will be featured in the podcast.

Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

Digital health is a technology that appeared only a few years ago. Up to now, it was very often overlooked. The current situation is helping digital health to show it's full potential. For example, Digital health can be used as a triage system, finding out first what kind of illness a patient has with chatbots and telemedicine solutions. Afterward, the patients can be referred to real-life doctors - to the right one.

A solution Symptoma has developed. In this episode, I am talking with the CEO of Symptoma, Jama Nateqi, about the real potential of digital health.

Another novel technology appeared recently - blockchain. Astrid Woollard, Partner at Scytale Ventures, is investing in companies that develop blockchain-based solutions. She has joined us to chat about the leverage blockchain can provide for digital health and the entire healthcare system.

Speaker:
Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Scytale Ventures (https://scytale.ventures/)
Symptoma (https://www.symptoma.com/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers in the Q&A. The best questions will be featured in the podcast. Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

The LSG2G Partners
Experts in Life Science



This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

Viral threats to humankind like the Coronavirus need scientists from all over the world collaborating to solve the problem. People like Saara Inkinen support scientists and universities to transfer their inventions to companies who turn science into products.

These products help patients to overcome illnesses and stay healthy. In this episode you will get some information how Saara helps in that area.

More information:

Nordic Catalyst (https://www.nordiccatalyst.com/)
LSG2G (https://www.lifescienceget2gether.com/)

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

These days there is a lot of discussion about the development of diagnostics, therapeutics, and vaccines against the Coronavirus and it´s disease COVID 19. Viruses are one threat to the health of human beings. Bacteria is another one. Traditionally, bacterial infections are treated with antibiotics. Recently, some bacteria have developed antibiotic resistance.

The WHO describes that Antibiotic resistance is one of the biggest threats to global health, food security, and development today. (https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance)

Phagomed (https://www.phagomed.com/) is developing a novel approach to treat bacterial infections without antibiotics. How that works, the challenges a company has to face during the development of novel drugs, and why not all viruses are evil, you will hear in this episode.

More information: 

https://www.phagomed.com/
https://www.lifescienceget2gether.com/
https://linktr.ee/soschner

Do you want to learn more about life science?
Join exclusive future webinars and member-only events: Become a member of the LSG2G Network.

Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

This week I had the honor to moderate a panel discussion at the RESI conference (https://www.resiconference.com/). It is one of the most important meetings for early-stage investment in the United States. Life Science Nation is the organizer of the event series. Last year in March the RESI conference visited Europe for the first time. The city of choice was Vienna. I invited Dennis Ford and Greg Mannix to visit the Life Science Get2gether #8. 

At the RESI conference in Vienna, I had the opportunity to speak at the Panel - how business angels and family offices view seed and Series A rounds? At the time of the Bio US, I again supported the RESI conference as a speaker. This time we were talking about European Tech Hubs. 

This year the conference is back in Europe. Well, due to the actual situation with the Corona Virus the conference turned digital. Last Monday we recorded the European tech Hub panel. At the panel, I had the opportunity to speak with 3 speakers about their model and the situation for Investors in Europe.

Institutional life science investors such as VCs or family offices are looking for assets that are de-risked and have data packages that indicate potential efficacy and safety – however, reaching that point takes substantial funding that’s not easy to find. Life science entrepreneurs need novel funding and development solutions that help them overcome this steep funding challenge at the very earliest stage of company formation, typically in years 0-3 of a company’s life. In this RESI panel, the audience can learn about new initiatives that are creating opportunities for life science startups to thrive in Europe.

The speaker:

Jeroen Blokhuis, PhD is the Chief Business Officer of the Pivot Park in the Netherlands. Pivot Park is an 8-year young Dutch Science Park, formally the R&D campus of Organon, that in the past was acquired by Shering-Plough, then acquired by MSD, and then given back to municipality in 2012. The Pivot Park now houses 60+ biotech startups and scale-ups, including Acerta-Pharma.

Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI) serving all academic institutions in Vienna. She has a background in genetics and has worked with R&D-based deep-tech startups since 2004. INiTS has been ranked amongst the TOP20 UBIs worldwide since 2013 by UBI Global (ubi-global.com). INiTS’ startups outperform creating jobs, raising funds and finding strategic partners. Some examples are Apeptico, Lexogen, Marinomed (INiTS’ 1st IPO), MedicusAI, mySugr, S-TARget etc. She is co-founder of investorinnen.com (female investing) and Women in Health IT and since 2018 managing partner of healthhubvienna.com, an international acceleration program to drive innovation in healthcare. 

Olivier Nosjean is the Research Scientific Director at Servier. A biochemist by training, he has been a drug discovery researcher and manager for 20 years. He established and has been a contributor to a range of public/private partnerships throughout the world, focused on therapeutic innovation and on scientific and technology expertise. Olivier is currently leading the technology innovation strategy and the Program for PhD students and Post-docs at Servier. He is an active contributor to Servier initiatives related to open innovation, entrepreneurship and strategic partnerships. One of his most exciting actions today are dedicated to preparing the opening of a drug discovery incubator along with the new research site of Servier currently under construction.

More information:  Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

Michael Lukesch has recently closed his first financing round for Valanx Biotech. He started right after graduating into his entrepreneurial journey and cleared many obstacles on the way with excellence.

Valanx focuses on a novel approach for protein conjugation. Specific, fast, and cost-effective. The company is operating in lower Austria.

In the most recent episode of beginner's mind, Michael talks about how he brought himself to leap into entrepreneurship, navigating the rollercoaster ride of building a startup, what he learned at top-notch incubation programs like Rebel Bio and early-stage conferences like Biovaria.

More information at 

Michael Lukesch (https://www.linkedin.com/in/michaellukesch/) 
Valanx (valanx.bio)   
linktr.ee/soschner   
lifescienceget2gether.com   

 

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

Did you ever wonder: Whatever effort you spent with potential clients. The sales figure doesn’t go up. Instead, it is moving down. The more time you spent with potential clients, the less you sell. Well, trying to convince the unconvinceable might be the reason.
In this episode, Christian speaks about the importance of selecting the right approach towards potential customers.

Read the script to this episode at medium (https://medium.com/@christian.soschner/no-sales-that-might-be-the-reason-fe66eae649fa?source=friends_link&sk=21ac770d4dc263b21424493cf5fb9580)

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

How to turn a daily habit into an investment. Some thoughts on savings, investment and making money.

More information: 

Linktr.ee/soschner  

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

In 2017 I created the Life Science Network LSG2G. This is a brief overview of the history and the next event.

More information at lifescienceget2gether.com

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe

There is this thing that some people demand free work. My take on it. Script: https://medium.com/@christian.soschner/a-business-needs-paying-customers-7cb8f1c6e4a3?source=friends_link&sk=299243e18054aa66acb69b02ec31b56d

Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lsg2g.substack.com/subscribe